Protalix (PLX) Sr. VP & COO Naos Yaron Receives Stock Award

What Happened

• Naos Yaron, Senior Vice President & Chief Operating Officer of Protalix BioTherapeutics (PLX), was granted two derivative awards on 2026-09-03 totaling 168,000 units (112,000 and 56,000). Each award is reported at $0.00 per unit (no cash paid at grant).
• These are derivative equity awards (RSUs and/or stock-option-type awards as described in the filing). The grants do not represent an open-market purchase or sale — they are compensation awards that will convert to shares or become exercisable if and when they vest.

Key Details

• Transaction date and price: 2026-09-03; acquired at $0.00 per unit.
• Total awarded: 168,000 derivative units (112,000 + 56,000).
• Shares owned after transaction: Not disclosed in the Form 4 provided.
• Vesting: Footnotes state the shares underlying the stock options vest in 12 equal quarterly installments commencing on the grant date (F1) and each RSU represents the right to receive one share and vests in 12 equal quarterly installments from grant (F3, F4).
• Existing option holdings: Filing notes additional outstanding options not part of this grant — 60,000 @ $5.60 (exp. 9/13/2028); 122,656 @ $3.59 (exp. 8/11/2030); 340,000 @ $1.03 (exp. 9/7/2032); 100,000 @ $1.10 (exp. 9/23/2034); 50,000 @ $1.64 (exp. 9/3/2035) (F2).
• Filing timeliness: Form filed 2026-09-04 for a 2026-09-03 grant — appears timely (filed next business day).

Context

• These awards are typical executive compensation grants. RSUs convert to shares on vesting; options (if any) require exercise at their strike price upon vesting. Because the grants were reported at $0, no cash was exchanged at grant and these do not indicate an open-market purchase or sale.
• For retail investors: new awards indicate the executive was granted more potential equity, but value depends on vesting and the company’s future share price.